Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07217392). This is a study registration, not published results. Lead sponsor: Abbott Medical Devices. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 200 participants (ESTIMATED). Conditions: Bradycardia, Right Ventricular Pacing, Heart Failure, Atrial Fibrillation (AF), Cardiac Disease, Left Bundle Branch Area Pacing, Conduction System Pacing. Interventions: DEVICE: LBBAP lead. Primary outcome measures: Infection Rate , 0-6 months; Perforation Rate , 0-6 months; Malfunction Rate , 0-6 months; Cardiovascular Injury Rate , 0-6 months; Implant success rate , At the time of implant; Lead dislodgement rate , 0-6 months; Pacing threshold , 0-6 months; Impedence , 0-6 months; Sensing Amplitude , 0-6 months. Brief summary: The objective of this study is to evaluate the safety and effectiveness of LBBA pacing/sensing in patients implanted with the Tendril STS 2088TC or UltiPace LPA1231 lead through 6 months post-implant.